{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:10:01Z","timestamp":1793329801441,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Assessing clinical tumor response following completion of total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer is paramount to select patients for watch-and-wait treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess organ preservation (OP) and oncologic outcomes according to clinical tumor response grade.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This was secondary analysis of the Organ Preservation in Patients with Rectal Adenocarcinoma trial, a phase 2, nonblinded, multicenter, randomized clinical trial. Randomization occurred between April 2014 and March 2020. Eligible participants included patients with stage II or III rectal adenocarcinoma. Data analysis occurred from March 2022 to July 2023.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Patients were randomized to induction chemotherapy followed by chemoradiation or chemoradiation followed by consolidation chemotherapy. Tumor response was assessed 8 (\u00b14) weeks after TNT by digital rectal examination and endoscopy and categorized by clinical tumor response grade. A 3-tier grading schema that stratifies clinical tumor response into clinical complete response (CCR), near complete response (NCR), and incomplete clinical response (ICR) was devised to maximize patient eligibility for OP.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>OP and survival rates by clinical tumor response grade were analyzed using the Kaplan-Meier method and log-rank test.<\/jats:p><\/jats:sec>Results<\/jats:title>There were 304 eligible patients, including 125 patients with a CCR (median [IQR] age, 60.6 [50.4-68.0] years; 76 male [60.8%]), 114 with an NCR (median [IQR] age, 57.6 [49.1-67.9] years; 80 male [70.2%]), and 65 with an ICR (median [IQR] age, 55.5 [47.7-64.2] years; 41 male [63.1%]) based on endoscopic imaging. Age, sex, tumor distance from the anal verge, pathological tumor classification, and clinical nodal classification were similar among the clinical tumor response grades. Median (IQR) follow-up for patients with OP was 4.09 (2.99-4.93) years. The 3-year probability of OP was 77% (95% CI, 70%-85%) for patients with a CCR and 40% (95% CI, 32%-51%) for patients with an NCR (P<\/jats:italic>\u2009&amp;lt;\u2009.001). Clinical tumor response grade was associated with disease-free survival, local recurrence-free survival, distant metastasis-free survival, and overall survival.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this secondary analysis of a randomized clinical trial, most patients with a CCR after TNT achieved OP, with few developing tumor regrowth. Although the probability of tumor regrowth was higher for patients with an NCR compared with patients with a CCR, a significant proportion of patients achieved OP. These findings suggest the 3-tier grading schema can be used to estimate recurrence and survival outcomes in patients with locally advanced rectal cancer who receive TNT.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02008656<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.50903","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:03:33Z","timestamp":1704816213000},"page":"e2350903","source":"Crossref","is-referenced-by-count":149,"title":["Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy"],"prefix":"10.1001","volume":"7","author":[{"given":"Hannah M.","family":"Thompson","sequence":"first","affiliation":[{"name":"Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Omer","sequence":"additional","affiliation":[{"name":"Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin K.","family":"Kim","sequence":"additional","affiliation":[{"name":"Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan B.","family":"Yuval","sequence":"additional","affiliation":[{"name":"Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris S.","family":"Verheij","sequence":"additional","affiliation":[{"name":"Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Xuan","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Gollub","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham Jing-Ching","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Lee","sequence":"additional","affiliation":[{"name":"Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Quantitative Sciences, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram F.","family":"Hezel","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Center, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Marcet","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Cataldo","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blase N.","family":"Polite","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Herzig","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liska","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Oommen","sequence":"additional","affiliation":[{"name":"Department of Surgery, John Muir Health, Walnut Creek, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Friel","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital, University of Virginia Health System, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Ternent","sequence":"additional","affiliation":[{"name":"Department of Surgery, Creighton University Medical Center, Omaha, Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Coveler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Surgery, Washington University, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Garcia-Aguilar","sequence":"additional","affiliation":[{"name":"Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"OPRA Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"9","key":"zoi231490r1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"key":"zoi231490r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2022.101774","article-title":"Watch and wait: why, to whom and how.","volume":"43","author":"Cerd\u00e1n-Santacruz","year":"2022","journal-title":"Surg Oncol"},{"issue":"6","key":"zoi231490r3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/SLA.0000000000002761","article-title":"Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis.","volume":"268","author":"Dattani","year":"2018","journal-title":"Ann Surg"},{"issue":"7","key":"zoi231490r4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.","volume":"2","author":"Dossa","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"23","key":"zoi231490r5","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy.","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"issue":"35","key":"zoi231490r6","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","article-title":"Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.","volume":"29","author":"Maas","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi231490r7","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1097\/SLA.0b013e3182759f1c","article-title":"Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy.","volume":"256","author":"Smith","year":"2012","journal-title":"Ann Surg"},{"issue":"10139","key":"zoi231490r8","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"zoi231490r9","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1097\/SLA.0000000000003738","article-title":"Management and outcome of local regrowths in a watch-and-wait prospective cohort for complete responses in rectal cancer.","volume":"274","author":"van der Sande","year":"2021","journal-title":"Ann Surg"},{"issue":"1","key":"zoi231490r10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/SLA.0b013e3182196e1f","article-title":"Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.","volume":"254","author":"Garcia-Aguilar","year":"2011","journal-title":"Ann Surg"},{"issue":"3","key":"zoi231490r11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.radonc.2016.03.017","article-title":"Timely tumor response analysis after preoperative chemoradiotherapy and curative surgery in locally advanced rectal cancer: a multi-institutional study for optimal surgical timing in rectal cancer.","volume":"119","author":"Kwak","year":"2016","journal-title":"Radiother Oncol"},{"issue":"7","key":"zoi231490r12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/DCR.0b013e31828aedcb","article-title":"Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature.","volume":"56","author":"Foster","year":"2013","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"zoi231490r13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1245\/s10434-017-6213-8","article-title":"Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response?","volume":"25","author":"Hupkens","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"zoi231490r14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/bjs\/znad051","article-title":"Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD).","volume":"110","author":"Temmink","year":"2023","journal-title":"Br J Surg"},{"issue":"4","key":"zoi231490r15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"issue":"7","key":"zoi231490r16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/bjs.8700","article-title":"The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy.","volume":"99","author":"Smith","year":"2012","journal-title":"Br J Surg"},{"key":"zoi231490r17","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s12885-015-1632-z","article-title":"Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.","volume":"15","author":"Smith","year":"2015","journal-title":"BMC Cancer"},{"issue":"7","key":"zoi231490r18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.6004\/jnccn.2020.0032","article-title":"NCCN guidelines insights: rectal cancer, version 6.2020.","volume":"18","author":"Benson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"zoi231490r19","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/DCR.0b013e3181f42b89","article-title":"Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.","volume":"53","author":"Habr-Gama","year":"2010","journal-title":"Dis Colon Rectum"},{"issue":"29","key":"zoi231490r20","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.3748\/wjg.v26.i29.4218","article-title":"Watch and wait approach in rectal cancer: current controversies and future directions.","volume":"26","author":"L\u00f3pez-Campos","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"8","key":"zoi231490r21","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1200\/JCO.1999.17.8.2396","article-title":"Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial.","volume":"17","author":"Francois","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi231490r22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s10350-004-6579-0","article-title":"Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.","volume":"46","author":"Stein","year":"2003","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"zoi231490r23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10350-003-0062-1","article-title":"Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection.","volume":"47","author":"Moore","year":"2004","journal-title":"Dis Colon Rectum"},{"issue":"12","key":"zoi231490r24","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1002\/bjs.6377","article-title":"Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis.","volume":"95","author":"Kerr","year":"2008","journal-title":"Br J Surg"},{"issue":"3","key":"zoi231490r25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.semradonc.2011.02.002","article-title":"Rectal cancer: primary staging and assessment after chemoradiotherapy.","volume":"21","author":"Evans","year":"2011","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"zoi231490r26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/SLA.0000000000000368","article-title":"Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies.","volume":"263","author":"Petrelli","year":"2016","journal-title":"Ann Surg"},{"issue":"1","key":"zoi231490r27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clcc.2017.10.012","article-title":"Optimal interval to surgery after neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.","volume":"17","author":"Du","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"7","key":"zoi231490r28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/DCR.0000000000001338","article-title":"Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think!","volume":"62","author":"Habr-Gama","year":"2019","journal-title":"Dis Colon Rectum"},{"issue":"4","key":"zoi231490r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5896","article-title":"Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy.","volume":"5","author":"Smith","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi231490r30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1470-2045(15)00467-2","article-title":"Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.","volume":"17","author":"Renehan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi231490r31","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S2468-1253(18)30301-7","article-title":"Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis.","volume":"3","author":"Chadi","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"zoi231490r32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10151-022-02654-5","article-title":"Local tumor regrowth after clinical complete response following neoadjuvant therapy for rectal cancer: what happens when organ preservation falls short.","volume":"27","author":"Cerd\u00e1n-Santacruz","year":"2023","journal-title":"Tech Coloproctol"},{"issue":"1","key":"zoi231490r33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/DCR.0000000000002494","article-title":"The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the International Watch and Wait Database.","volume":"66","author":"Fernandez","year":"2023","journal-title":"Dis Colon Rectum"},{"issue":"15","key":"zoi231490r34","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2011.39.7901","article-title":"Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.","volume":"30","author":"Park","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi231490r35","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1200\/JCO.2013.54.3769","article-title":"Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO\/ARO\/AIO-94 trial.","volume":"32","author":"Fokas","year":"2014","journal-title":"J Clin Oncol"},{"issue":"34","key":"zoi231490r36","doi-asserted-by":"publisher","first-page":"8688","DOI":"10.1200\/JCO.2005.02.1329","article-title":"Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.","volume":"23","author":"R\u00f6del","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi231490r37","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1245\/s10434-021-09827-w","article-title":"Endoscopic feature and response reproducibility in tumor assessment after neoadjuvant therapy for rectal adenocarcinoma.","volume":"28","author":"Felder","year":"2021","journal-title":"Ann Surg Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2813744\/thompson_2024_oi_231490_1741961525.74825.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:03:59Z","timestamp":1742400239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2813744"}},"subtitle":["A Secondary Analysis of the OPRA Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50903","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]}}}